7.24

3.85% -0.29

After Hours: 7.34 0.10 +1.38%

Achieve Life Sciences Inc (ACHV)

Overview News Price History Option Chain Financials Why ACHV Down? Discussions Forecast Stock Split

Achieve Life Sciences Inc stock is traded at $7.24, with a volume of 1.89M. It is down -3.85% in the last 24 hours and down -14.62% over the past month. Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

Previous Close:

$7.53

Open:

$7.62

24h Volume:

1.89M

Relative Volume:

1.25

Market Cap:

$745.01M

Revenue:

Net Income/Loss:

$-51.99M

P/E Ratio:

-6.4904

EPS:

-1.1155

Net Cash Flow:

$-45.31M

1W Performance:

-3.98%

1M Performance:

-14.62%

6M Performance:

+124.15%

1Y Performance:

+126.96%

1-Day Range:

$7.05

$7.63

1-Week Range:

$7.05

$8.28

52-Week Range:

$2.62

$8.64

Achieve Life Sciences Inc Stock (ACHV) Company Profile

Name

Achieve Life Sciences Inc

Sector

Healthcare (1064)

Industry

Biotechnology (595)

Phone

425-686-1500

Address

22722 29TH DR. SE, SEATTLE, BC

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

ACHV's Discussions on Twitter

Compare ACHV vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACHV Achieve Life Sciences Inc	7.24	775.88M	0	-51.99M	-45.31M	-1.1155
VRTX Vertex Pharmaceuticals Inc	504.73	133.37B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	190.01	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	735.20	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.21	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.64	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Initiated	Canaccord Genuity	Buy
Nov-25-25	Initiated	Citizens JMP	Mkt Outperform
Aug-21-25	Initiated	H.C. Wainwright	Buy
Nov-14-24	Initiated	Rodman & Renshaw	Buy
Sep-27-24	Initiated	Raymond James	Strong Buy
May-10-23	Reiterated	Maxim Group	Buy
Jun-23-21	Initiated	Oppenheimer	Outperform

View All

Achieve Life Sciences Inc Stock (ACHV) Latest News

Oct 01, 2026

Achieve Life Sciences appoints Benjamin Halladay as chief financial officer By Investing.com - Investing.com Canada

Oct 01, 2026

Achieve Life Sciences names Benjamin Halladay as CFO By Investing.com - Investing.com Nigeria

Oct 01, 2026

Achieve Life Sciences appoints Benjamin Halladay as CFO - TradingView

Oct 01, 2026

Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer - Yahoo Finance

Oct 01, 2026

Sep 30, 2026

Stifel initiates coverage of Achieve Life Sciences with Buy rating, $18 price target - TradingView

Sep 30, 2026

Stifel Initiates Achieve Life Sciences (ACHV) with Buy Rating on Cytisinicline Potential - GuruFocus

Sep 30, 2026

Achieve a new Buy at Stifel on potential of smoking cessation drug cytisinicline - Seeking Alpha

Sep 30, 2026

Achieve Life Sciences (NASDAQ:ACHV) Shares Gap UpStill a Buy? - MarketBeat

Sep 30, 2026

ACHV Initiates Coverage On by Stifel -- Rating Set to Buy, PT $1 - GuruFocus

Sep 30, 2026

Stifel Initiates Achieve Life Sciences at Buy With $18 Price Target - marketscreener.com

Sep 30, 2026

Sep 29, 2026

Operating cash flow per share of Achieve Life Sciences, Inc. – HAN:SP4P - TradingView

Sep 29, 2026

Stifel initiates Achieve Life Sciences stock with buy rating By Investing.com - Investing.com South Africa

Sep 29, 2026

Stifel initiates Achieve Life Sciences stock with buy rating - Investing.com

Sep 29, 2026

Achieve Life Sciences (NASDAQ:ACHV) Share Price Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat

Sep 29, 2026

Sep 28, 2026

A yearlong quit-smoking and vaping study involved 475 adults. Results will be presented Oct. 20. - Stock Titan

Sep 28, 2026

Sep 24, 2026

Achieve Life Sciences (ACHV) Short Interest & Short Float | Updated Sep 2026 - MarketBeat

Sep 24, 2026

Sep 23, 2026

Achieve Life Sciences: Thesis Intact, Setup Remains Constructive (Rating Downgrade) (ACHV) - Seeking Alpha

Sep 23, 2026

Sep 22, 2026

Achieve Life Sciences: A Funded Manufacturing Reset, Not A Broken Clinical Thesis - Seeking Alpha

Sep 22, 2026

Sep 21, 2026

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Sep 21, 2026

Sep 18, 2026

Achieve Life Sciences (NASDAQ:ACHV) Stock Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat

Sep 18, 2026

Sep 17, 2026